UnknownPhase 2

Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

Israel49 participantsStarted 2020-01-01

Plain-language summary

A few studies have documented that some patients can be down-staged from an initially inoperable state to a potentially resectable state. Five-year survival in initially inoperable patients that ultimately come to a complete resection appears to be similar to patients who are resected at first presentation. The investigators goal is to assess the rate of conversion to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Subject Inclusion Criteria: * Histologically confirmed colorectal adenocarcinoma metastatic to the liver. * The patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. * A patient may have had prior chemotherapy or be previously untreated. * ECOG PS \<2 Subject Exclusion Criteria: * Prior radiation, hepatic thermo ablation or resection (other than biopsy) to the liver. * Patient may not have received prior treatment with hepatic artery infusion (HAI). * Extrahepatic metastases * Female patients who are pregnant or lactating

What they're measuring

conversion rate to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.

Timeframe: 2 years

Trial details

NCT IDNCT04003792

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01

Contact for this trial

Eran Sadot, MD

+972-3-9376201 eransadot@gmail.com